Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Learn More

Stock
Quote

Volume:

04/26/2023 2:01 PMEDT

Press
Releases

05/05/2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

04/03/2023

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

03/14/2023

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

02/01/2023

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

Webcasts

Financial Information

Document Date	Description	Form	View
09/02/2020	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	DRS	View HTML 0001213900-20-025064.pdf 0001213900-20-025064.rtf 0001213900-20-025064.xls
01/26/2021	Registration statement for face-amount certificate companies	S-1	View HTML 0001213900-21-004399.pdf 0001213900-21-004399.rtf 0001213900-21-004399.xls
02/09/2021	Amended Registration statement for face-amount certificate companies	S-1/A	View HTML 0001213900-21-007715.pdf 0001213900-21-007715.rtf 0001213900-21-007715.xls
02/12/2021	Registration of certain classes of securities 12(b) of the Securities Exchange Act	8-A12B	View HTML 0001213900-21-008871.pdf 0001213900-21-008871.rtf 0001213900-21-008871.xls
02/16/2021	Registration of up to an additional 20% of securities for any offering registered on an S-1	S-1MEF	View HTML 0001213900-21-009861.pdf 0001213900-21-009861.rtf 0001213900-21-009861.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009867.pdf 0001213900-21-009867.rtf 0001213900-21-009867.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009868.pdf 0001213900-21-009868.rtf 0001213900-21-009868.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009870.pdf 0001213900-21-009870.rtf 0001213900-21-009870.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009873.pdf 0001213900-21-009873.rtf 0001213900-21-009873.xls
02/16/2021	Initial filing by director officer or owner of more than ten percent.	3	View HTML 0001213900-21-009875.pdf 0001213900-21-009875.rtf 0001213900-21-009875.xls

Contact
IR

Send us an investor-related question using the form below.